Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2023 Publisher: Santen Oy, Niittyhaankatu 20, 33720, Tampere, Finland
TRUSOPT is indicated:
in the treatment of elevated intra-ocular pressure in:
When used as monotherapy, the dose is one drop of dorzolamide in the conjunctival sac of the affected eye(s), three times daily.
When used as adjunctive therapy with an ophthalmic beta-blocker, the dose is one drop of dorzolamide in the conjunctival sac of the affected eye(s), two times daily.
When substituting dorzolamide for another ophthalmic anti-glaucoma agent, discontinue the other agent after proper dosing on one day, and start dorzolamide on the next day.
If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.
Patients should be instructed to wash their hands before use and avoid allowing the tip of the container to come into contact with the eye or surrounding structures.
Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
Patients should be informed of the correct handling of the containers.
Limited clinical data in paediatric patients with administration of dorzolamide three times a day are available. (For information regarding paediatric dosing see section 5.1.)
OCUMETER PLUS containers only:
Only limited information is available with regard to human overdose by accidental or deliberate ingestion of dorzolamide hydrochloride.
The following have been reported with oral ingestion: somnolence; topical application: nausea, dizziness, headache, fatigue, abnormal dreams, and dysphagia.
Treatment should be symptomatic and supportive. Electrolyte imbalance, development of an acidotic state, and possible central nervous system effects may occur. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.
3 years.
After first opening the container, TRUSOPT should be used no longer than 28 days.
Store container in original carton in order to protect from light.
This medicinal product does not require any special temperature storage conditions.
For storage conditions after first opening of the medicinal product, see section 6.3.
TRUSOPT container contains 5 ml of solution. Two alternate containers may be marketed.
White translucent low-density polyethylene (LDPE) container with a transparent linear LDPE dropper tip and a white polypropylene (PP) cap or OCUMETER Plus Ophthalmic Dispenser consists of a translucent, high-density polyethylene container with a sealed dropper tip, a flexible fluted side area which is depressed to dispense the drops, and a 2-piece cap assembly. The 2-piece cap mechanism punctures the sealed dropper tip upon initial use, then locks together to provide a single cap during the usage period. Tamper evidence is provided by a safety strip on the container label.
TRUSOPT is available in the following packaging configurations:
1 × 5 ml (single 5-ml container)
3 × 5 ml (three 5-ml containers)
6 × 5 ml (six 5-ml containers)
Not all pack sizes may be marketed.
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.